SLC5A2 and diabetic kidney disease: Initiate SGLT2 inhibitors for DKD at the dose with evidence ofcardiorenal benefit (ie, canagliflozin 100 mg daily, dapagliflozin10 mg daily, empagliflozin 10 mg daily).